nach oben

Erschienen in:

01.03.2020 | Clinical study

Myositis with immune checkpoint inhibitors in a real-world setting

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Although myositis is an infrequent adverse drug reaction (ADR) in a real-world setting for patients receiving immune checkpoint inhibitors (ICIs), according to study results reported in the Annals of the Rheumatic Diseases, "myositis was reported more than 17 times with ICI agents than with any other drugs". …

Nguyen T, et al. Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database. Annals of the Rheumatic Diseases : 17 Feb 2020. Available from: URL: http://dx.doi.org/10.1136/annrheumdis-2020-217018

Titel: Myositis with immune checkpoint inhibitors in a real-world setting
Publikationsdatum: 01.03.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75807-7

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Lamotrigine

Epinephrine

Olmesartan medoxomil

Enoxaparin sodium/heparin/warfarin

Methotrexate overdose

Voriconazole